Stengone Carmine N. 4
4 · Contineum Therapeutics, Inc. · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
Contineum (CTNM) CEO Carmine Stengone Sells Shares After Exercising Options
What Happened Carmine N. Stengone, CEO, President and a director of Contineum Therapeutics (CTNM), exercised stock option/derivative awards and immediately sold the resulting shares under a pre-established trading plan. On Feb 24, 2026 he exercised 4,400 shares at $1.26/share (cost $5,544) and sold those 4,400 shares for total proceeds reported as $70,486. On Feb 25, 2026 he exercised 2,700 shares at $1.26/share (cost $3,402) and sold those 2,700 shares for total proceeds reported as $43,242. Combined, 7,100 shares were sold for reported gross proceeds of $113,728; the exercise cash paid was $8,946.
Key Details
- Transaction dates: Feb 24, 2026 (4,400 shares) and Feb 25, 2026 (2,700 shares). Form filed Feb 26, 2026.
- Exercise price paid: $1.26 per share for the exercised options (total exercise cost $8,946).
- Sale price (weighted averages reported): $16.02 per share for the sold shares (proceeds $70,486 and $43,242). Footnotes state sale price ranges: 4,400-share sales at $16.00–$16.15 and 2,700-share sales at $16.00–$16.05.
- These transactions were effected pursuant to a 10b5-1 trading plan adopted Sept 23, 2025 (footnote).
- Options were fully vested and exercisable (footnote).
- Shares owned after the transactions are not specified in the Form 4 filing.
- Filing shows no indication that the report was late.
Context
- This was an exercise of vested options followed by open-market sales (commonly a cashless or immediate sale after exercise). Such transactions are routinely executed under pre-set 10b5-1 plans and are not, by themselves, a clear signal of insider sentiment.
Insider Transaction Report
- Exercise/Conversion
Class A Common Stock
[F1]2026-02-24$1.26/sh+4,400$5,544→ 19,354 total - Sale
Class A Common Stock
[F1][F2]2026-02-24$16.02/sh−4,400$70,486→ 14,954 total - Exercise/Conversion
Class A Common Stock
[F1]2026-02-25$1.26/sh+2,700$3,402→ 17,654 total - Sale
Class A Common Stock
[F1][F3]2026-02-25$16.02/sh−2,700$43,242→ 14,954 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F4]2026-02-24−4,400→ 123,617 totalExercise: $1.26Exp: 2028-11-13→ Class A Common Stock (4,400 underlying) - Exercise/Conversion
Stock Option (right to buy)
[F1][F4]2026-02-25−2,700→ 120,917 totalExercise: $1.26Exp: 2028-11-13→ Class A Common Stock (2,700 underlying)
Footnotes (4)
- [F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
- [F4]The stock options are fully vested and exercisable.